ReviewCancers2021
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2025Pooled it
- Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients.Frontiers in pharmacology · 2025Pooled it
- Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Meta-analysis revisiting the influence ofPharmacogenomics · 2024Pooled it
- Pooled it
- Real-world analysis of genotype-guided treatment for carriers of actionable DPYD and UGT1A1 variants.The pharmacogenomics journal · 2026Article
- Clinical Implications ofPharmaceutics · 2026Review
- Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment.JCO precision oncology · 2026Article
- Article
- Microbiome-derived cancer: the catabolism of bilirubin to urobilin in the liver-gut axis and its consequences.Gastroenterology report · 2026Review
- Expert Consensus on the Diagnosis and Management of Inherited Hyperbilirubinemia (2025).Journal of clinical and translational hepatology · 2026Article
- Bilirubin in Parkinson's disease: pathogenic mechanisms and therapeutic potentials.Frontiers in neuroscience · 2026Review
- [Expert consensus on the diagnosis and therapy of inherited hyperbilirubinemia (version 2025)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Integrative analysis of epigenetic and transcriptional interrelations identifies histotype-specific biomarkers in early-stage ovarian carcinoma.Journal of ovarian research · 2025Article
- Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.The oncologist · 2025Article
- Restore intestinal steady-state: new advances in the clinical management of chemotherapy-associated diarrhea and constipation.Journal of molecular histology · 2025Review
- An evaluation of the performance of the PAP-PCR method in detecting UGT1A1 gene polymorphisms.Molecular biology reports · 2025Article
- Article
- Allele frequency of genetic variations related to theJournal of diabetes and metabolic disorders · 2024Article
- Correction: Nelson et al.Cancers · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Multi-gene assays often include
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.